Medindia

X

ALK1 Protein Plays a Key Role in Binding LDL Cholesterol

by Shirley Johanna on  November 21, 2016 at 11:33 PM Research News   - G J E 4
A protein that plays an important role in the buildup of LDL (low-density lipoprotein) cholesterol in blood vessels has been identified by a team of researchers from the Yale University. The finding could lead to an additional strategy to block LDL accumulation, which could help prevent or slow the clogging of arteries that leads to heart disease, the researchers said.
ALK1 Protein Plays a Key Role in Binding LDL Cholesterol
ALK1 Protein Plays a Key Role in Binding LDL Cholesterol
Advertisement

Arteries become clogged with fats and cholesterol when certain proteins in the body, known as lipoproteins, combine with and transport fats in the blood to cells. Scientists have long believed that the LDL receptor molecule was responsible for the transport of LDL within cells. But given that some individuals lacking the LDL receptor still have high levels of LDL, questions remained about the mechanism.

‘The protein called ALK1 is an LDL-binding protein that initiates the early phases of atherosclerosis. A therapeutic approach to block ALK1 could help prevent atherosclerosis.’
Advertisement
To identify the mechanism, the research team screened more than 18,000 genes from the endothelium -- the inner layer of human blood vessels. They examined the transfer of LDL into endothelial cells and then focused on possible genes involved in the process.

The researchers found that a protein called ALK1 facilitated LDL's pathway into cells. "We confirmed that ALK1 directly binds to LDL," said William C. Sessa, senior author and the Alfred Gilman Professor of Pharmacology and professor of medicine (cardiology). The team also determined that the "LDL-ALK1 pathway" aided the transport of LDL from blood into tissue.

The role of ALK1 in LDL accumulation was not previously known, said Sessa.

"The discovery of ALK1 as an LDL-binding protein implies that it might initiate the early phases of atherosclerosis," he noted. "If we can find a way of blocking ALK1 using small molecules or antibodies, it might be used in combination with lipid-lowering strategies." Current lipid-lowering strategies include statins, which target LDL cholesterol levels in the blood.

A therapeutic that blocks ALK1 "would be a unique strategy for reducing the burden of atherosclerosis and be synergistic with lipid- lowering therapies," Sessa noted.

Heart disease caused by damage to blood vessels is the leading cause of death worldwide.

The study was published in Nature Communications.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All